Literature DB >> 15904921

Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice.

Jing Zhang1, Yi Li, Jieli Chen, Yisheng Cui, Mei Lu, Stanton B Elias, James B Mitchell, Lora Hammill, Padmavathy Vanguri, Michael Chopp.   

Abstract

We investigated the treatment of remitting-relapsing experimental autoimmune encephalomyelitis (EAE) in mice with human bone marrow stromal cells (hBMSCs). hBMSCs were injected intravenously into EAE mice upon onset of paresis. Neurological functional tests were scored daily by grading clinical signs (score 0-5). Immunohistochemistry was performed to measure the transplanted hBMSCs, cell proliferation (bromodeoxyuridine, BrdU), oligodendrocyte progenitor cells (NG2), oligodendrocytes (RIP), and brain-derived neurotrophic factor (BDNF). The maximum clinical score and the average clinical scores were significantly decreased in the hBMSC-transplanted mice compared to the phosphate-buffered-saline-treated EAE controls, indicating a significant improvement in function. Demyelination significantly decreased, and BrdU(+) and BDNF(+) cells significantly increased in the hBMSC-treated mice compared to controls. Some BrdU(+) cells were colocalized with NG2(+) and RIP(+) immunostaining. hBMSCs also significantly reduced the numbers of vessels containing inflammatory cell infiltration. These data indicate that hBMSC treatment improved functional recovery after EAE in mice, possibly, via reducing inflammatory infiltrates and demyelination areas, stimulating oligodendrogenesis, and by elevating BDNF expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15904921     DOI: 10.1016/j.expneurol.2005.03.018

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  121 in total

1.  Multipotent Mesenchymal Stromal Cells for Autoimmune Diseases.

Authors:  Alan Tyndall
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

Review 2.  The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Authors:  Jeffery J Auletta; Amelia M Bartholomew; Richard T Maziarz; Robert J Deans; Robert H Miller; Hillard M Lazarus; Jeffrey A Cohen
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

3.  Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes.

Authors:  Changhui Zhou; Bo Yang; Yi Tian; Hongliang Jiao; Wendi Zheng; Jian Wang; Fangxia Guan
Journal:  Cell Immunol       Date:  2011-09-29       Impact factor: 4.868

Review 4.  Cellular therapy of systemic sclerosis.

Authors:  Jacob M van Laar; Alan Tyndall
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

5.  The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.

Authors:  Rina Aharoni; Raya Eilam; Hagit Domev; Galya Labunskay; Michael Sela; Ruth Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

6.  Bone-marrow-derived mesenchymal stem cells promote proliferation and neuronal differentiation of Niemann-Pick type C mouse neural stem cells by upregulation and secretion of CCL2.

Authors:  Hyun Lee; Ji Eun Kang; Jong Kil Lee; Jae-Sung Bae; Hee Kyung Jin
Journal:  Hum Gene Ther       Date:  2013-06-21       Impact factor: 5.695

7.  Adult stem cells and multiple sclerosis.

Authors:  N Scolding
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

8.  Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Authors:  Moa Fransson; Elena Piras; Hao Wang; Joachim Burman; Ida Duprez; Robert A Harris; Katarina LeBlanc; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

9.  Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis.

Authors:  Yael Barhum; Sharon Gai-Castro; Merav Bahat-Stromza; Ran Barzilay; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2009-11-10       Impact factor: 3.444

10.  Neurological functional recovery after thymosin beta4 treatment in mice with experimental auto encephalomyelitis.

Authors:  J Zhang; Z G Zhang; D Morris; Y Li; C Roberts; S B Elias; M Chopp
Journal:  Neuroscience       Date:  2009-09-25       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.